 Kimi Kondo
Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiology | 4 | 2017 | 159 | 0.660 |
Why?
| | Lymphocele | 1 | 2013 | 2 | 0.430 |
Why?
| | Curriculum | 4 | 2018 | 920 | 0.390 |
Why?
| | Surgery, Computer-Assisted | 1 | 2013 | 77 | 0.390 |
Why?
| | Faculty | 1 | 2013 | 137 | 0.380 |
Why?
| | Kidney Neoplasms | 4 | 2016 | 348 | 0.290 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 546 | 0.280 |
Why?
| | Kidney Transplantation | 1 | 2013 | 670 | 0.270 |
Why?
| | Clinical Competence | 1 | 2013 | 1017 | 0.250 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1098 | 0.240 |
Why?
| | Ultrasonography, Interventional | 2 | 2016 | 128 | 0.230 |
Why?
| | Angiomyolipoma | 2 | 2016 | 17 | 0.230 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2016 | 41 | 0.220 |
Why?
| | Internship and Residency | 1 | 2013 | 1050 | 0.210 |
Why?
| | Diagnostic Imaging | 2 | 2016 | 325 | 0.200 |
Why?
| | Students, Medical | 2 | 2017 | 322 | 0.180 |
Why?
| | Education, Medical, Undergraduate | 2 | 2018 | 178 | 0.150 |
Why?
| | Radiology, Interventional | 1 | 2018 | 30 | 0.150 |
Why?
| | Schools, Medical | 2 | 2018 | 136 | 0.140 |
Why?
| | Vena Cava Filters | 1 | 2017 | 60 | 0.130 |
Why?
| | Pregnancy, Abdominal | 1 | 2016 | 2 | 0.130 |
Why?
| | Thromboembolism | 1 | 2017 | 112 | 0.130 |
Why?
| | Radiology Information Systems | 1 | 2016 | 28 | 0.130 |
Why?
| | Biotechnology | 1 | 2016 | 39 | 0.130 |
Why?
| | Teaching | 1 | 2018 | 217 | 0.130 |
Why?
| | Tuberous Sclerosis | 1 | 2016 | 49 | 0.130 |
Why?
| | Laboratories | 1 | 2017 | 108 | 0.130 |
Why?
| | Prosthesis Design | 1 | 2017 | 309 | 0.120 |
Why?
| | Organizational Innovation | 1 | 2016 | 139 | 0.120 |
Why?
| | Venous Thrombosis | 1 | 2017 | 177 | 0.120 |
Why?
| | Hypertension, Portal | 1 | 2016 | 61 | 0.120 |
Why?
| | Cavernous Sinus | 1 | 2015 | 17 | 0.120 |
Why?
| | Venous Insufficiency | 1 | 2015 | 12 | 0.120 |
Why?
| | Radiography, Interventional | 1 | 2016 | 105 | 0.120 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 212 | 0.120 |
Why?
| | Methotrexate | 1 | 2016 | 249 | 0.120 |
Why?
| | Arteriovenous Fistula | 1 | 2015 | 35 | 0.120 |
Why?
| | Portal Vein | 1 | 2016 | 108 | 0.120 |
Why?
| | Personal Satisfaction | 1 | 2017 | 201 | 0.120 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2015 | 50 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 442 | 0.110 |
Why?
| | Radiology Department, Hospital | 1 | 2014 | 15 | 0.110 |
Why?
| | Hernia, Abdominal | 1 | 2013 | 7 | 0.110 |
Why?
| | Ascites | 1 | 2013 | 44 | 0.110 |
Why?
| | Hernia, Inguinal | 1 | 2013 | 35 | 0.100 |
Why?
| | Intestinal Obstruction | 1 | 2013 | 49 | 0.100 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2013 | 48 | 0.100 |
Why?
| | Embolization, Therapeutic | 1 | 2015 | 207 | 0.100 |
Why?
| | Cholangiocarcinoma | 1 | 2013 | 77 | 0.100 |
Why?
| | Translocation, Genetic | 1 | 2012 | 96 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2016 | 10219 | 0.090 |
Why?
| | Radiography | 1 | 2013 | 797 | 0.090 |
Why?
| | Education, Medical | 1 | 2014 | 251 | 0.090 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 118 | 0.090 |
Why?
| | Disease Progression | 3 | 2013 | 2627 | 0.080 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2012 | 231 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2012 | 752 | 0.080 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2010 | 55 | 0.080 |
Why?
| | Carcinoma, Papillary | 1 | 2009 | 77 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 898 | 0.080 |
Why?
| | Piperazines | 1 | 2011 | 340 | 0.080 |
Why?
| | Neuroblastoma | 1 | 2010 | 151 | 0.080 |
Why?
| | Pyrazoles | 1 | 2012 | 404 | 0.070 |
Why?
| | Pyridines | 1 | 2012 | 478 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2013 | 639 | 0.070 |
Why?
| | Lung Neoplasms | 2 | 2012 | 2342 | 0.070 |
Why?
| | Pyrimidines | 1 | 2011 | 459 | 0.070 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2009 | 226 | 0.070 |
Why?
| | DNA Methylation | 1 | 2011 | 611 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2012 | 887 | 0.060 |
Why?
| | Anatomic Landmarks | 2 | 2016 | 28 | 0.060 |
Why?
| | United States | 4 | 2018 | 13871 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 5415 | 0.060 |
Why?
| | Aged | 5 | 2016 | 22061 | 0.060 |
Why?
| | Humans | 15 | 2018 | 129625 | 0.050 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1049 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 4 | 2016 | 2512 | 0.050 |
Why?
| | Young Adult | 4 | 2016 | 12455 | 0.040 |
Why?
| | Male | 6 | 2016 | 63670 | 0.040 |
Why?
| | Incidence | 2 | 2016 | 2641 | 0.040 |
Why?
| | Intergenerational Relations | 1 | 2017 | 22 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2011 | 1282 | 0.030 |
Why?
| | Forecasting | 1 | 2018 | 361 | 0.030 |
Why?
| | Inventions | 1 | 2016 | 18 | 0.030 |
Why?
| | Hemoperitoneum | 1 | 2016 | 12 | 0.030 |
Why?
| | Female | 8 | 2016 | 68734 | 0.030 |
Why?
| | Career Choice | 1 | 2018 | 207 | 0.030 |
Why?
| | Device Removal | 1 | 2017 | 136 | 0.030 |
Why?
| | History, 20th Century | 1 | 2017 | 294 | 0.030 |
Why?
| | Portography | 1 | 2016 | 11 | 0.030 |
Why?
| | Portal Pressure | 1 | 2016 | 4 | 0.030 |
Why?
| | Pregnancy, Ectopic | 1 | 2016 | 52 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2016 | 115 | 0.030 |
Why?
| | Delayed Diagnosis | 1 | 2016 | 79 | 0.030 |
Why?
| | Operative Time | 1 | 2016 | 124 | 0.030 |
Why?
| | Radiation Exposure | 1 | 2016 | 45 | 0.030 |
Why?
| | Models, Organizational | 1 | 2016 | 145 | 0.030 |
Why?
| | Fluoroscopy | 1 | 2016 | 157 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2016 | 143 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2016 | 154 | 0.030 |
Why?
| | Program Development | 1 | 2017 | 355 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 509 | 0.030 |
Why?
| | Time Factors | 2 | 2016 | 6555 | 0.030 |
Why?
| | Adult | 5 | 2016 | 35599 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2016 | 14522 | 0.030 |
Why?
| | Carbon Dioxide | 1 | 2016 | 259 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2016 | 281 | 0.030 |
Why?
| | Contrast Media | 1 | 2016 | 393 | 0.030 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 65 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 875 | 0.020 |
Why?
| | Ultrasonography | 1 | 2016 | 712 | 0.020 |
Why?
| | Bile Duct Neoplasms | 1 | 2013 | 99 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2013 | 515 | 0.020 |
Why?
| | Laparoscopy | 1 | 2016 | 450 | 0.020 |
Why?
| | Genes, Neoplasm | 1 | 2011 | 20 | 0.020 |
Why?
| | Middle Aged | 4 | 2016 | 31136 | 0.020 |
Why?
| | Adolescent | 3 | 2016 | 20412 | 0.020 |
Why?
| | Genotype | 1 | 2016 | 1833 | 0.020 |
Why?
| | Imatinib Mesylate | 1 | 2011 | 75 | 0.020 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2011 | 50 | 0.020 |
Why?
| | Reoperation | 1 | 2013 | 541 | 0.020 |
Why?
| | Data Collection | 1 | 2014 | 650 | 0.020 |
Why?
| | ras Proteins | 1 | 2012 | 144 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2012 | 168 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 851 | 0.020 |
Why?
| | Benzamides | 1 | 2011 | 203 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 259 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1843 | 0.020 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2012 | 201 | 0.020 |
Why?
| | Risk Factors | 2 | 2013 | 9786 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 843 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 756 | 0.020 |
Why?
| | Genome, Human | 1 | 2011 | 394 | 0.020 |
Why?
| | Kidney | 1 | 2016 | 1386 | 0.020 |
Why?
| | Nephrectomy | 1 | 2010 | 158 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 611 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1616 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 607 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2011 | 778 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2012 | 636 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 282 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1269 | 0.020 |
Why?
| | Cisplatin | 1 | 2009 | 299 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1499 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 3080 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1491 | 0.020 |
Why?
| | Cell Line | 1 | 2012 | 2784 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2016 | 5756 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 958 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3186 | 0.010 |
Why?
| | Pregnancy | 1 | 2016 | 6417 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4404 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 7052 | 0.010 |
Why?
| | Infant | 1 | 2016 | 8995 | 0.010 |
Why?
| | Child, Preschool | 1 | 2016 | 10490 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 3774 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1560 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 3717 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 2046 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3394 | 0.010 |
Why?
| | Child | 1 | 2016 | 20884 | 0.010 |
Why?
|
|
Kondo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|